What Happens When You Stop Taking GLP-1 Weight Loss Medications | Research

The takeaway

Discontinuing GLP-1 and other incretin-based weight loss drugs typically leads to significant weight regain and reversal of cardiometabolic benefits.

Up to 50% stop within 1-2 years
Due to side effects, cost, access issues, or inadequate response

What the researchers found

Discontinuation of incretin-based obesity medications results in weight regain and reversal of cardiometabolic improvements, with up to 50% of patients stopping treatment within 1-2 years.

Why it matters

With millions of patients starting GLP-1 medications, understanding discontinuation outcomes and having management plans for treatment gaps is critical for real-world obesity care.

How the study worked

Clinical review synthesizing evidence on outcomes following discontinuation of obesity pharmacotherapies, with practical interim management strategies.

What this study cannot tell us

Review article — synthesizes existing evidence rather than generating new data. Discontinuation patterns may vary across healthcare systems and insurance coverage models.

How to read the evidence

Clinical review summarizing existing trial and observational data — provides practical guidance based on available evidence.

When this study was published

Published in 2026; reflects the latest discontinuation data for current incretin therapies.

The bigger picture

This highlights a fundamental challenge in obesity medicine: current pharmacotherapies require indefinite use, raising questions about healthcare system sustainability and the need for treatments with more durable effects.

Questions still open

Can any intervention prevent weight regain after stopping GLP-1 medications?
Should obesity medications be viewed as lifelong treatments similar to blood pressure medications?

Common questions

Will I gain weight back if I stop my GLP-1 medication?

Research shows most patients regain a significant portion of lost weight after discontinuing GLP-1 medications, though the amount varies. Working with your doctor on a transition plan can help minimize regain.

Why do people stop taking weight loss medications?

Common reasons include side effects (mainly GI), cost and insurance coverage issues, supply shortages, and feeling that adequate weight loss has been achieved.

Read the original research

Approach to the Patient: Clinical Outcomes and Interim Strategies Following Discontinuation of Incretin Agonists.

The Journal of clinical endocrinology and metabolism, 111(3), 870-878

View on PubMed ↗Publisher’s paper ↗

Citation

Barenbaum, Sarah R; Aras, Mohini; Kashyap, Sangeeta; Aronne, Louis J. (2026). Approach to the Patient: Clinical Outcomes and Interim Strategies Following Discontinuation of Incretin Agonists.. The Journal of clinical endocrinology and metabolism, 111(3), 870-878. https://doi.org/10.1210/clinem/dgaf641